[{"orgOrder":0,"company":"Avia Pharma","sponsor":"Nemysis","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Financing","leadProduct":"Iron Hydroxide Adipate Tartrate","moa":"Iron","graph1":"Hematology","graph2":"Phase III","graph3":"Avia Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Avia Pharma \/ Avia Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Avia Pharma \/ Avia Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by Avia Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : The financing aims to fund the clinical development of IHAT (iron hydroxide adipate tartrate), which is being evaluated for the treatment of iron deficiency.

                          Product Name : IHAT

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Undisclosed

                          March 18, 2025

                          Lead Product(s) : Iron Hydroxide Adipate Tartrate

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Recipient : Nemysis

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank